Clinical Research Genetics Pharma Companies Regulation 
Drug Discovery World
SEPTEMBER 28, 2022
Its application in pharma, most commonly in drug discovery, has been steadily growing with global partnerships between tech vendors and pharma companies becoming more commonplace. Another big problem looms for organisations attempting to access these private data sets; ever-stricter data privacy laws.
pharmaphorum
DECEMBER 21, 2021
Additionally, the work being done within Rare Disease networks, formed of specialty sites, pharma companies, CROs, researchers, and other stakeholders, can all benefit from the value generated by real world genomic data, as outlined by panellist Dr Joanne Hackett, Head of Genomic and Precision medicine at IQVIA.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cloudbyz
MAY 19, 2021
Moreover, 12% of industrial clinical pipeline products and at least 16% of preclinical pipeline products consist of CGT. The primary drivers for growth include increasing cancer and genetic cases and predicated applicability of CGT as a treatment.
The Pharma Data
DECEMBER 17, 2020
Most recently, Cadavid served as senior vice president and Head of Clinical Development at Fulcrum Therapeutics where he led the development of multiple small molecules for the treatment of genetically defined rare diseases. AB2 Bio – Swiss pharma company AB2 Bio Ltd. Immune Regulation – U.K.-based
pharmaphorum
MAY 26, 2022
Inadequate clinical trial representations of all populations can therefore leave underrepresented groups vulnerable due to the lack of subgroup-specific data. While many pharma companies are actively working on initiatives to improve diversity in clinical trials, we still have a long way to go.
pharmaphorum
SEPTEMBER 1, 2020
.” This public-spirited industry still required greater oversight, however, and government regulations on medicines increased on both sides of the Atlantic. Thalidomide and the development of drug safety regulation and monitoring. George Merck on the cover of Time magazine.
XTalks
OCTOBER 1, 2020
Lin has made several transitions throughout her career, from being a clinician at an academic center, to academic research, to heading business development in industry. Working on finding therapies for genetic diseases at NeuBase, Dr. Sooter says, “Everyday, we get up and that’s our goal and it really drives everyone.
Expert insights. Personalized for you.
52 
Let's personalize your content